

AWARD NUMBER: W81XWH-14-1-0580

TITLE: Synergistic Action of FOXP3 and TSC1 Pathways During Tumor Progression

PRINCIPAL INVESTIGATOR: Lihong Wang, M.D.; Ph.D.

CONTRACTING ORGANIZATION: University of Alabama at Birmingham, Birmingham, AL  
35294

REPORT DATE: October 2016

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;  
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

# REPORT DOCUMENTATION PAGE

*Form Approved*  
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. **PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.**

|  |                    |                                 |                                   |   |  |
|--|--------------------|---------------------------------|-----------------------------------|---|--|
| <b>1. REPORT DATE</b><br>October 2016  |                    | <b>2. REPORT TYPE</b><br>Annual |                                   | <b>3. DATES COVERED</b><br>29 Sep2015-28 Sep 2016   |  |
| <b>4. TITLE AND SUBTITLE</b><br>Synergistic Action of FOXP3 and TSC1 Pathways During Tumor Progression   |                    |                                 |                                   | <b>5a. CONTRACT NUMBER</b>  |  |
|  |                    |                                 |                                   | <b>5b. GRANT NUMBER</b><br>W81XWH-14-1-0580   |  |
|  |                    |                                 |                                   | <b>5c. PROGRAM ELEMENT NUMBER</b>   |  |
| <b>6. AUTHOR(S)</b><br>Lizhong Wang, M.D.; Ph.D.<br><br>E-Mail: lwang12@uab.edu  |                    |                                 |                                   | <b>5d. PROJECT NUMBER</b>   |  |
|  |                    |                                 |                                   | <b>5e. TASK NUMBER</b>  |  |
|  |                    |                                 |                                   | <b>5f. WORK UNIT NUMBER</b>   |  |
| <b>7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)</b><br><br>University of Alabama at Birmingham, 701 S 20 <sup>th</sup> St, Birmingham, AL 35294  |                    |                                 |                                   | <b>8. PERFORMING ORGANIZATION REPORT NUMBER</b><br><br>Mercer University, 4700 Waters Ave, Savannah, GA 31404 |  |
| <b>9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)</b><br><br>U.S. Army Medical Research and Materiel Command<br>Fort Detrick, Maryland 21702-5012   |                    |                                 |                                   | <b>10. SPONSOR/MONITOR'S ACRONYM(S)</b>   |  |
|  |                    |                                 |                                   | <b>11. SPONSOR/MONITOR'S REPORT NUMBER(S)</b>   |  |
| <b>12. DISTRIBUTION / AVAILABILITY STATEMENT</b><br><br>Approved for Public Release; Distribution Unlimited  |                    |                                 |                                   |   |  |
| <b>13. SUPPLEMENTARY NOTES</b>   |                    |                                 |                                   |   |  |
| <b>14. ABSTRACT</b><br>Foxp3, the first identified X-linked prostate tumor suppressor, represses c-Myc in both the mouse and human prostate. Dysfunction of the Foxp3-c-Myc axis may lead to prostate cancer initiation. Tsc1 and Foxp3 double-deletions in the mouse prostate led to prostate carcinoma at an early age. In this proposed study, we observed that deletion of Tsc1 led to a constitutive mTOR activation and subsequently increases phosphorylation of c-Myc at threonine 58 (pT58) and decreases phosphorylation at serine 62 (pS62). Furthermore, loss of Foxp3 transcriptionally induces c-Myc expression and loss of Tsc1 activates mTOR signaling, leading a cross-talk between Foxp3-c-Myc and Tsc1-mTOR signaling pathways that converges on c-Myc and promoted tumor progression. This observation will help us understand how double Foxp3 and Tsc1 deficiencies promote tumor progression of prostate cancer. |                    |                                 |                                   |   |  |
| <b>15. SUBJECT TERMS</b><br>Prostate cancer, Tumor progression, Gene therapy, Transcriptional regulation, Post-translational modification  |                    |                                 |                                   |   |  |
| <b>16. SECURITY CLASSIFICATION OF:</b>   |                    |                                 | <b>17. LIMITATION OF ABSTRACT</b> | <b>18. NUMBER OF PAGES</b>  | <b>19a. NAME OF RESPONSIBLE PERSON</b>           |
| <b>a. REPORT</b>   | <b>b. ABSTRACT</b> | <b>c. THIS PAGE</b>             |                                   |   | <b>USAMRMC</b>                                   |
| U  | U                  | U                               | UU                                | 19  | <b>19b. TELEPHONE NUMBER</b> (include area code) |

## Table of Contents

|   | <u>Page</u> |
|---|-------------|
| <b>1. Introduction.....</b>   | <b>4</b>    |
| <b>2. Keywords.....</b>   | <b>6</b>    |
| <b>3. Accomplishments.....</b>                                      | <b>6</b>    |
| <b>4. Impact.....</b>   | <b>13</b>   |
| <b>5. Changes/Problems.....</b>                                     | <b>14</b>   |
| <b>6. Products.....</b>   | <b>14</b>   |
| <b>7. Participants &amp; Other Collaborating Organizations.....</b> | <b>14</b>   |
| <b>8. Special Reporting Requirements.....</b>                       | <b>14</b>   |
| <b>9. Appendices.....</b>   | <b>14</b>   |

## INTRODUCTION

Human prostate cancer is thought to be a heterogeneous population of mutant cells caused by the accumulation of mutations in tumor-related genes within multiple signaling pathways. These accumulated mutations may cause the transformation of benign prostatic epithelium to prostatic intraepithelial neoplasia (PIN), with progression to invasive carcinoma and, ultimately, metastatic disease [1-3]. Mouse models of PIN (mPIN) generated by a single-mutant gene in prostate do not progress to invasive carcinoma [1, 2]. However, overexpression of *c-Myc* or conditional deletion of *Pten* in mouse prostate epithelium most accurately replicates the development of human prostate cancer [4, 5], suggesting that the *c-Myc*- or *Pten*-signaling pathways have a critical role in prostate tumor progression.

*FOXP3* at Xp11.23 is a member of the forkhead-box/winged-helix transcription factor family. This gene functions as the master regulator in the development and function of regulatory T cells [6]. However, *FOXP3* is also expressed in epithelial tissues of the breast, lung, and prostate [7]. Nuclear *FOXP3* is observed in normal human prostate epithelial cells but is lost in approximately 70% of human prostate cancers [8]. In prostate cancer samples, *FOXP3* is frequently inactivated by deletion (14%) or somatic mutation (25%) by a single-hit inactivation mechanism [8]. *FOXP3* mutations reported in prostate cancer cells abrogate normal *FOXP3* function by disrupting its nuclear translocation [8]. Moreover, an inverse correlation exists between *FOXP3* and *c-MYC* expression in human primary prostate cancers [8]. *FOXP3*-mediated transcriptional repression of *c-MYC* is necessary to control *c-MYC* levels in normal prostate epithelial cells [9]. Indeed, inactivation of *FOXP3* contributes to the widespread overexpression of *c-MYC* in prostate cancer [8] while ectopic expression of wild-type (WT) *FOXP3* induces substantial growth inhibition of prostate cancer cell lines [8]. Lineage-specific ablation of *Foxp3* in mouse prostate epithelial cells leads to mPIN, as well as a dramatic increase in both *c-Myc* mRNA and protein expression, further suggesting that *Foxp3* is a critical repressor for the *c-Myc* locus [8]. These data indicate that *FOXP3* is an X-linked tumor suppressor in both the mouse and human prostate, and suggest that genetic alteration of *FOXP3* is an early event in prostate carcinogenesis.

The PI3K/Akt/Tsc1/2/mTOR signaling pathway is upregulated in 30–50% of prostate cancers, often through loss of PTEN suppressor function [10, 11]. Recent studies that systematically analyzed large cohorts of human prostate cancer patients to identify mutated genes in aggressive and metastatic prostate cancer confirmed that the most frequently mutated genes are *PIK3CA* (4% mutation and 15–20% amplification) and *PTEN* (4% mutation and 30–39% deletion) [12, 13]. Notably, the mutated or deleted genes identified in prostate cancer cells lead to constitutive activation of PI3K/AKT/mTOR signaling [13, 14]. Mice heterozygous for *Pten* deletion develop mPIN with 100% incidence, and homozygous deletion of *Pten* in the prostate induces aggressive prostate cancer [5, 15, 16]. Mutant *Akt1* transgenic mice develop mPIN with pathologic similarity to mPIN in *Pten*<sup>+/-</sup> mice [17]. Ultimately, PI3K/Akt signaling activates mTOR, and enhanced levels of mTOR and its downstream targets are observed in prostate cancer [18]. Importantly, genetic loss of *Akt1*, *mTOR*, or *eIF4E* (mTOR downstream target) is sufficient to significantly reduce the initiation of prostate cancer in the *Pten* conditional knockout mouse model [19-21]. Overall, these genetic studies demonstrate the importance of the PI3K/Akt/mTOR pathway in prostate cancer development and progression. Tsc1 is an essential component of the mTOR pathway. Either phosphorylation of the Tsc1/2 complex by Akt or loss of Tsc1/2 facilitates mTOR activation [22, 23]. *Tsc1*-deficient mice develop mPIN in the lateral

and anterior prostate by 27 weeks of age, with increasing disease penetrance over time [24], and lateral prostate lesions progress to prostate carcinoma in 16- to 22-month old mutant mice [24]. Thus, release of Tsc1-dependent mTOR inhibition is sufficient to initiate prostate tumor progression. While genetic alterations in *TSC1/2* have not been reported previously in human prostate cancers, a missense mutation (G1034C) of *TSC1* was identified in the prostate cancer cell line DU145 ([www.mskcc.org](http://www.mskcc.org)).

While there are no reports citing a direct connection between Tsc1 and Foxp3 or c-Myc, the role of Tsc1 opposes that of c-Myc in cell growth and proliferation [25-27]. c-Myc activation appears to correlate with PI3K/Akt/mTOR signaling in prostate cancer [28], but the underlying molecular mechanisms remain unknown. However, three potential possibilities exist. 1) mTOR directly regulates c-Myc stability: Expression of c-Myc is affected by phosphorylation at the conserved residues threonine 58 (T58) and serine 62 (S62). Phosphorylation at S62 (pS62) stabilizes c-Myc, while phosphorylation at T58 (pT58) promotes c-Myc ubiquitylation and is required for its degradation [29-31]. Results from recent studies suggest that c-Myc is regulated by proteins identified in phosphorylation peptide libraries of mTOR complex 1 (mTORC1), one of the complexes through which mTOR functions [32, 33]. Thus, mTOR activity may affect the stability of c-Myc through phosphorylation. 2) Reciprocal induction of c-Myc and the 4E-BP1 complex increases c-Myc expression: 4E-BP1 levels correlate with amplification of c-Myc in prostate cancer [34] and eIF4E activity increases c-Myc expression [35], while c-Myc overexpression also increases 4E-BP1 activity [34, 35] and induces translation initiation by the 4E-BP1 complex [36, 37]. 3) A feed-forward loop with c-Myc and the Tsc1/2 complex increases c-Myc: Loss of c-Myc increases *Tsc2* expression, which further represses c-Myc expression [26, 27], suggesting a functional c-Myc-Tsc2 loop. Thus, conversely, increased c-Myc with additional Tsc1 defects may completely relieve mTOR inhibition by the Tsc1/2 complex, inducing constitutive mTOR activation. In addition, a co-occurrence of c-MYC amplification and PI3K/mTOR pathway alteration has been observed in human prostate cancer, raising the possibility that these two genetic hits cooperate to promote tumor progression, and mouse models show that this cooperation accelerates progression of mPIN to microinvasive cancer [38]. Thus, it is important to determine whether there is a functional interaction of the Foxp3-c-Myc axis and Tsc1/2-mTOR pathway during tumor progression.

The mTORC1 inhibitor rapamycin reverses early mPIN lesions in young *Akt1* transgenic mice, but results were modest in *Pten* conditional knockout models [39, 40]. Moreover, recent clinical trials have shown that tumor resistance to rapamycin limits the efficacy of rapamycin or its analogues in inhibiting prostate cancer progression (ID: NCT00629525; <http://www.clinicaltrials.gov>). It has been proposed that these drugs do not completely block mTOR or other signaling pathways working in concert with the PI3K/mTOR pathway; the latter explanation has been supported by recent studies. Cells lacking c-Myc are sensitive to rapamycin, suggesting that some components of the mTOR pathway may be regulated by c-Myc [27]. Early studies suggested that c-Myc regulates the mTOR-targeting 4E-BP1 complex to control cell growth [36, 37], and recent studies revealed that c-Myc abrogates sensitivity to rapamycin through regulation of 4E-BP1 complex [34, 41], but its ability to confer rapamycin-resistance is not fully understood [34]. Furthermore, *in vivo* analysis showed that c-Myc expression can disrupt the elimination of mPIN lesions in young *Akt* mutant mice treated with mTOR inhibitors [38]. Thus, inhibition of c-Myc expression may be an effective means of alleviating resistance to mTOR inhibitors. In this proposed study, we will take advantage of our mouse models of prostate cancer to estimate the synergetic anti-tumor effects of co-treating mice with inhibitors of


mTOR and c-MYC, a regimen that may prevent the development of tumor resistance to mTOR inhibitors.

## KEYWORDS

Prostate cancer, Tumor progression, Gene therapy, Transcriptional regulation, Post-translational modification

## ACCOMPLISHMENTS

Our preliminary studies provide evidence that the *Foxp3*-c-Myc axis and *Tsc1*-mTOR signaling pathways converge during tumor progression. First, lineage-specific ablation of *Foxp3* in mouse prostate leads to prostate hyperplasia and mPIN [8], but this does not occur when these mice are crossed with c-Myc-deficient mice, suggesting the *Foxp3*-c-Myc axis regulates tumor initiation. Second, introduction of a prostate-specific deletion of *Tsc1* into *Foxp3* mutant mice leads to prostate carcinoma at an early age, suggesting that the deletion of *Tsc1* accelerates *Foxp3*-related tumor progression. This phenotype was supported in human primary prostate cancers in which FOXP3 defects were often accompanied by deletions of *TSC1*. Third, *Foxp3* can transcriptionally inhibit c-Myc expression [8] and mTOR can control c-Myc phosphorylation in prostate cancer cells. Since *Tsc1* is an upstream inhibitor of mTOR [22, 23], c-Myc is likely to be a bridge for the cross-talk between *Foxp3* and *Tsc1* in tumor progression. Therefore, our central hypothesis is that dysfunction of both *Foxp3* and *Tsc1* synergistically promotes tumor progression through regulation of c-Myc transcription and phosphorylation/stabilization in prostate cancer (Fig. 1). Our overall goal is to define the mechanisms regulating the cross-talk between *Foxp3* and *Tsc1* in tumor progression and improve existing therapeutic strategies in prostate cancer.



## Task 1: IACUC approvals for mouse studies

The animal protocol has been approved by both the UAB IACUC and the USAMRMC Animal Care and Use Review Office (ACURO)


### Specific Aim 1: To characterize the functional cross-talk between Foxp3 and Tsc1 in vitro

#### Task 2: Determine the cross-talk between Foxp3 and Tsc1 in vitro

**Task 2a:** The cross-talk among Tsc1, mTOR, c-Myc and Foxp3 in *Tsc1*<sup>-/-</sup> and *Tsc1*<sup>+/+</sup> MEF (2-12 months)

#### 1. Tsc1-mTOR signaling modulates the phosphorylation and stabilization of c-Myc in MEF

To test if Tsc1 is implicated to c-Myc stability, we determined the half-life of c-Myc after treatment with the protein synthesis inhibitor cycloheximide (CHX) in mouse *Tsc1*<sup>-/-</sup> and *Tsc1*<sup>+/+</sup> MEF. While c-Myc was degraded after 30 min of treatment with CHX, the c-Myc degradation was more delayed in *Tsc1*<sup>-/-</sup> MEF than in *Tsc1*<sup>+/+</sup> MEF (**Fig. 2A**), indicating that *Tsc1*-deficiency stabilizes c-Myc in MEF. Furthermore, we observed that *Tsc1* knockout resulted in the simultaneous increase of pS62-c-Myc and decrease of pT58-c-Myc by a comparison of *Tsc1*<sup>-/-</sup> and *Tsc1*<sup>+/+</sup> MEF (**Fig. 2B**), suggesting that the phosphorylation state of c-Myc is affected by Tsc1-deficiency.




**Figure 2. Tsc1 regulates the phosphorylation of c-Myc through mTOR signaling pathway in MEF.** **A**, c-Myc degradation in MEF after treatment with cycloheximide (CHX, 100  $\mu$ g/ml) for 2 hours. **B**, expression levels of pT58/pS62-c-Myc in *Tsc1*<sup>+/+</sup> MEF and *Tsc1*<sup>-/-</sup> MEF. **C**, expression levels of pT58/pS62-c-Myc and mTOR activation in *Tsc1*<sup>-/-</sup> MEF after inhibition of mTOR with Torin1 or silencing of mTOR with siRNAs. T58: threonine 58; S62: serine 62; p: phosphorylation; siRNA, small interfering RNA; MEF, mouse embryonic fibroblasts; min, minute.

Tsc1 is an essential component of the mTOR pathway and loss of Tsc1/2 facilitates mTOR activation [22, 23]. Thus, we investigated the effect of mTOR on expression of pT58/pS62-c-Myc in MEF. In *Tsc1*<sup>-/-</sup> MEF, the simultaneous increase of pS62-c-Myc and decrease of pT58-c-Myc were observed after inhibition of mTOR with Torin1, a mTOR inhibitor of both mTORC1 and mTORC2 [32, 42, 43], or silencing of mTOR with siRNAs (**Fig. 2C**). The effective inhibition of mTOR activation was validated by a downregulation of p-mTOR and pS6. This data suggests a post-translational regulation of the phosphorylation and stabilization of c-Myc by Tsc1-mTOR signaling.

## 2. Synergistic cross-talk between Foxp3 and Tsc1 in the regulation of c-Myc in MEF

To determine the role of *Foxp3* in *Tsc1*-dependent regulation of pT58/pS62-c-Myc, we transfected *Foxp3* into both *Tsc1*<sup>-/-</sup> and *Tsc1*<sup>+/+</sup> MEF. The exogenous *Foxp3* effectively blocked an increase of pS62-c-Myc by *Tsc1*-deficiency, while pT58-c-Myc appears to be lightly increased after *Foxp3* transfection in *Tsc1*<sup>-/-</sup> MEF. However, total c-Myc levels were dramatically reduced after *Foxp3* transfection in both *Tsc1*<sup>-/-</sup> and *Tsc1*<sup>+/+</sup> MEF (**Fig. 3A**). This data suggests a synergistic effect of *Foxp3* and *Tsc1* on c-Myc expression levels in MEF.

We observed that pT58/pS62-c-MYC is controlled by *Tsc1*-mTOR signaling (**Fig. 2B, C**), but it remains unknown whether this regulation is direct or indirect. Using siRNA, we identified that silencing of either mTOR or 4EBP1 attenuates the *Tsc1*-dependent regulation of pT58/pS62-c-Myc in MEF (**Fig. 2C and 3B**). However, it is still difficult to distinguish whether pT58/pS62-c-Myc levels are regulated by mTOR directly or through the 4E-BP1 complex, which can also induce c-Myc [34-37] and may, therefore, have a role in c-Myc phosphorylation and subsequent activity. In addition, *Tsc2*, *Gsk3β*, *Pin1*, *PP2A*, *Cdk2*, and *MAPK* [26, 27, 44-47] may also be implicated in the *Tsc1*-dependent regulation of c-Myc. However, we did not find any changes of these proteins in absence or present of *Tsc1* and *Foxp3* in MEF (**Fig. 3B**), supporting a direct regulation of c-Myc phosphorylation by mTOR or its substrates.




**Task 2b:** The cross-talk among FOXP3, TSC1, mTOR, and c-MYC in prostate cancer cells (2-9 months)

### 1. Functional cross-talk between FOXP3 and TSC1 in the regulation of c-Myc in prostate cancer cells

To confirm the involvement of *TSC1* in regulating c-MYC in prostate cancer cells, we used siRNAs to silence human *TSC1* normally expressed in androgen-dependent prostate cancer cell line LNCaP. While total c-MYC levels were not changed, the simultaneous increase of pS62-c-Myc and decrease of pT58-c-Myc were observed after silencing of *TSC1* with siRNAs in LNCaP cells (**Fig. 4A**). The *TSC1*-dependent mTOR activation was also validated by increased expression levels of p-mTOR, p-4EBP1, and pS6. Next, we treated the androgen-independent prostate cancer cell line DU145 with mTOR inhibitors rapamycin and Torin1. Treatment for 2h

with high-dose rapamycin or Torin1 induced pT58-c-Myc and reduced pS62-c-Myc levels (**Fig. 4B**). This data suggests that inhibition of mTOR increases pT58-c-Myc and lightly decreases pS62-c-Myc but not at total c-MYC levels. This finding shows the first evidence that Tsc1-mTOR signaling regulates c-Myc phosphorylation in prostate cancer cells. Since *TSC1* is mutated and expressed only at low levels in DU145 cells, to validate the cross-talk between FOXP3 and TSC1 in prostate cancer cells, we will transfect WT *TSC1* and WT *FOXP3* into the DU145 cells and compare the levels of c-MYC and mTOR and their phosphorylation states. As shown in **Figure 4C**, an increase in pT58-c-Myc and a decrease in pS62-c-Myc were observed after *TSC1* transfection, but total c-MYC were reduced by transfections with both *TSC1* and *FOXP3*, suggesting that FOXP3 and TSC1 converge to inhibit c-MYC expression in prostate cancer cells. Thus, we provided a regulatory mechanism of the cross-talk between FOXP3 and




TSC1 in regulation of c-Myc function in prostate cancer cells.

## 2. Dual targeting c-MYC and mTOR signaling pathways is an effective therapeutic approach for inhibition of prostate cancer cell growth

While the molecular mechanism of c-Myc-induced resistance to mTOR inhibition is still unknown, cells lacking c-Myc do not become resistant to mTOR inhibitors [41, 48]. Therefore, one of our aims is to determine if combination therapy with mTOR and c-Myc inhibitors can overcome such resistance. Recently, an *in vitro* analysis revealed that the phosphorylation sites of mTORC1 substrates correlate strongly with the resistance to rapamycin [49]. Thus, the intrinsic capacity of a phosphorylation site to serve as an mTORC1 substrate is a major determinant of its sensitivity to mTOR inhibitors. Our data shows that c-Myc phosphorylation at T58 is regulated by high-dose rapamycin or Torin1 but is resistant to normal-dose rapamycin

(Fig. 4B), suggesting that this c-Myc phosphorylation site may be associated with resistance to rapamycin.

We tested the synergistic action by blocking mTOR and c-Myc activity with inhibitors of both proteins in three commonly used prostate cancer cell lines: DU145, PC3, and LNCaP (Fig. 5). The mTOR inhibitors included rapamycin, Torin1, INK128, and DG-2; the c-Myc inhibitors included JQ1, 10058-F4, and 10074-G5. To observe the synergistic action of mTOR and c-Myc inhibitors, we administered only half of the effective dosage of each drug to the prostate cancer cells. Several combinations of these inhibitors reduced cell growth, but the combination of Torin1 and 10058-F4 inhibited cell growth most substantially in all three cell lines (Fig.



5). Torin1 is an ATP-competitive mTOR inhibitor that directly inhibits both mTORC1 and mTORC2 and impairs cell growth and proliferation to a far greater degree than rapamycin [32, 42, 43, 50, 51]. At 250 nM, Torin1 completely inhibited proliferation and caused a G1/S cell cycle arrest in MEFs [51]. 10058-F4 is a c-Myc inhibitor that prevents the binding of c-Myc/Max dimers to DNA targets, downregulates c-Myc expression, abrogates various c-Myc-dependent functions, and induces cell-cycle arrest and apoptosis [52-55]. Treatment with 100 μM 10058-F4 over 72 h effectively inhibited cell growth in AML cells [52]. Thus, dual targeting c-MYC and mTOR signaling pathways by a combination of 10058-F4 and Torin1 is an effective therapeutic approach for inhibition of prostate cancer cell growth.

## **Specific Aim II: To validate the functional cross-talk between Foxp3 and Tsc1 *in vivo***


### **Task 3: Validate the cross-talk between Foxp3 and Tsc1 *in vivo***

**Task 3a:** The c-Myc expression and phosphorylation in the *Tsc1* and/or *Foxp3* knockout prostates (2-12 months)

#### **1. Prostate-specific deletion of *Tsc1* accelerates prostate tumor progression in *Foxp3* mutant mice**

We introduced a prostate-specific deletion of the potential tumor suppressor gene *Tsc1* into *Foxp3* mutant mice on a C57BL/6 background. *Tsc1/Foxp3* double-deletions in the mouse prostate led to tumor progression starting at 22 weeks of age, and 100% of these mice developed prostate carcinoma by 43 weeks of age (Fig. 6A-D). At high magnification, definitive alterations in nuclear and cytoplasmic features are evident in prostate tissue, including larger and more vesicular nuclei and more densely eosinophilic cytoplasm. Similar cytologic alterations are well characterized in a variety of early invasive carcinomas in humans [56]. Interestingly, these


features are reminiscent of high-grade PIN and associated invasive carcinoma (Gleason pattern 3) in human prostate cancer. In immunohistochemistry (IHC) analysis, increased Ki67<sup>+</sup> cells and



decreased E-cadherin<sup>+</sup> cells were observed in the cancer lesions compared with adjacent normal tissues (**Fig. 6B**), indicating high proliferative and potential metastatic tumor cells. In survival analysis, only double deletions of *Tsc1* and *Foxp3* leads to prostate carcinoma at an early age (**Fig. 6C**). Both *Foxp3* single-mutant mice and *Tsc1* single-mutant mice develop mPIN within one year [8, 24], but *Foxp3/Tsc1* double-mutant mice develop prostate cancer much earlier at 22 to 43 weeks of age (**Fig. 6D**), suggesting loss of both genes hastens tumor progression. These results suggest that *Tsc1/Foxp3* double-deletions facilitate malignant transformation, but the mechanism by which the interaction of *Foxp3* and *Tsc1* controls tumor progression remains to be clarified.

## 2. Double deletion of *Tsc1* and/or *Foxp3* changes c-Myc phosphorylation, expression and activation in mouse prostates

*Foxp3* deletion in the prostate increases c-Myc levels [8] and *Tsc1* deletion in the prostate increases mTOR activation [24], which may stabilize c-Myc protein by regulating its phosphorylation at T58 and S62 in prostate cancer cells (**Fig. 4**). Thus, c-Myc may be a bridge for the functional cross-talk between *Foxp3* and *Tsc1* in the double-mutant mice. We determined the levels of total c-Myc and pS62/pT58-c-Myc protein in prostates of *Foxp3*, *Tsc1*, and *Foxp3/Tsc1* double-mutant mice at 43 weeks of age by immunoblotting with specific antibodies. The levels of c-Myc protein were higher in the *Foxp3/Tsc1* double-mutant mice than in the single-mutant mice (**Fig. 7A and B**), suggesting that the tumor progression is mediated by a



**Figure 7. Double deletions *Foxp3* and *Tsc1* lead to increased activation of c-Myc through mTORC1 signaling pathway in mouse prostate.** **A**, The protein expressions of total and pT58/pS62-c-MYC using IHC analysis in prostate tissue of the *Foxp3* cKO, *Tsc1* cKO or *Foxp3/Tsc1* double cKO mice at 12 weeks of age. **B**, phosphorylation and expression of c-Myc and activation of mTOR in the *Foxp3* cKO, *Tsc1* cKO or *Foxp3/Tsc1* double cKO mice. **C**, c-Myc activity was determined in micro-dissected cells by mRNA levels of c-Myc target genes using qPCR in the mice at 43 weeks of age. Red and green boxes indicate c-Myc active and repressive genes, respectively. Horizontal lines represent the average values. *p* values were determined by 2-tailed *t* test. \* *p* < 0.05. T58: threonine 58; S62: serine 62; p: phosphorylation; cKO, prostate conditional knockout.

synergistic upregulation of c-Myc. Likewise, expression levels of p4E-BP1 and pS6 were also assessed in these mice and an upregulation of mTOR activation were also observed in *Tsc1* and *Foxp3/Tsc1* double-mutant mice. Furthermore, we obtained normal and cancer epithelial cells by a laser capture microdissection from mouse prostate and tumor tissues. The c-Myc activity was evaluated in the micro-dissected cells by measuring the mRNA expression levels of c-Myc target genes, such as *E2f2*, *Hk2*, *Cdc25A*, *Cdkn1a* and *Cdkn2b*, using quantitative PCR (qPCR). As shown in **Figure 7C**, the expression levels of c-Myc target genes is greater in activated genes *E2f2*, *Hk2* and *Cdc25A* but lower in repressed genes *Cdkn1a* and *Cdkn2b* in the cancer cells from double-mutant mice than in the mPIN cells from single-mutant mice, further suggesting that tumor progression in the double-mutant mice is caused by an elevated c-Myc function.

**Task 3b:** The synergistic action of Foxp3 and c-Myc phosphorylation in tumor progression (2-30 months).

This task still on going for observation in targeting mouse models, prostate c-Myc<sup>WT</sup> and c-Myc<sup>T58A</sup> knock-in mice, by ex vivo imaging (MIR, Medical Imaging Resources).

## IMPACT

We have validated our hypothesis *in vitro* and part of *in vivo* and identify of a novel genetic mechanism in the pathogenesis of prostate cancer progression.

### 1. Understanding the pathogenesis of prostate cancer progression

While c-Myc and mTOR are the most frequently activated proteins in prostate cancer, their interaction is largely untested. Ours is the first attempt to investigate the synergy between the Foxp3 and Tsc1 pathways during tumor progression. In human prostate cancer, FOXP3 defects are often accompanied by deletions of *TSC1*. Prostate-specific deletions of *Foxp3* and *Tsc1* in mice led to tumor progression at an early age. c-Myc is one of the most commonly overexpressed oncogenes in prostate cancer. However, the mechanisms regulating c-Myc function in prostate cancer remain largely unknown. Foxp3 inhibits c-Myc transcription, and our data in this proposed study suggest that mTOR signaling affects phosphorylation of c-Myc in prostate cancer cells. The relative levels of phosphorylation at specific positions within c-Myc determine its protein stability. In this proposed work, we identified the cross-talk between Foxp3 and Tsc1 that have a critical role in c-Myc expression and stability in prostate cancer cells and mouse prostate cancers. This mechanism will help to understand why double Foxp3 and Tsc1 deficiencies promote tumor progression of prostate cancer as well as to understand how c-Myc is activated and its role in tumor progression of prostate cancer.

### 2. Understanding the mechanism of resistance to mTOR inhibitors

The mTOR inhibitor rapamycin and its analogs have been used in clinical trials. Unfortunately, cancer cells eventually develop a resistance to rapamycin, which may be due to ineffective block of mTOR or other signaling pathways working in concert with the mTOR pathway. The latter explanation has been supported by recent studies. Cells lacking c-Myc are sensitive to the effects of rapamycin, but in mice, tumors overexpressing c-Myc are resistant to rapamycin, suggesting that c-Myc is involved in rapamycin-resistance. Since both mTOR and c-Myc are frequently activated in prostate cancer, dual targeting strategies may be an effective approach for prostate cancer therapy. In this proposed work, we tested a joint administration of rapamycin or a novel mTOR inhibitor (e.g., Torin1) with a c-Myc inhibitor (e.g., 10058-F4) in prostate cancer cells. While rapamycin was ineffective in the inhibition of cancer cell

proliferation, a combination of rapamycin with 10058-F4, especially Torin1 with 10058-F4 can overcome this resistance. This identification provides a promising therapeutic approach against prostate tumor progression for patients with resistance to mTOR inhibitors.

## CHANGES/PROBLEMS

None

## PRODUCTS

1. Liu R, Liu C, Chen D, Yang WH, Liu X, Liu CG, Dugas CM, Tang F, Zheng P, Liu Y and **Wang L\***. FOXP3 controls an miR-146/NFκB negative feedback loop that inhibits apoptosis in breast cancer cells. *Cancer Research*, 2015 Apr 15; 75(8):1703-13. PMID: 25712342.
2. Liu R, Yi B, Wei S, Yang WH, Har KM, Chauhan P, Zhang W, Mao X, Liu X, Liu CG and **Wang L\***. FOXP3-microRNA-146-NF-κB axis and therapy for precancerous lesions in prostate. *Cancer Research*, 2015 Apr 15;75(8):1714-24. PMID: 25712341.
3. Etikala DM, Liu R, **Wang L\***. FOXP3-microRNA-146-NF-κB as oncotarget. *Oncoscience*, 2015, Aug 26;2(10):839-40. PMID: 26682271
4. Meredith LJ, Wang CM, Nascimento L, Liu R, **Wang L**, Yang WH. The Key Regulator for Language and Speech Development, FOXP2, is a Novel Substrate for SUMOylation. *J Cell Biochem*. 2016 Feb;117(2):426-38. PMID: 26212494.
5. Zhang W, Yi B, Wang C, Chen D, Bae S, Wei S, Guo RJ, Lu C, Nguyen LL, Yang WH, Lillard JW, Zhang X, **Wang L\***, Liu R. Silencing of CD24 Enhances the PRIMA-1-Induced Restoration of Mutant p53 in Prostate Cancer Cells. *Clin Cancer Res*. 2016 May 15;22(10):2545-54. PMID: 26712693.
6. Zhang Y, Li B, Zhang X, Sonpavde GP, Jiao K, Zhang A, Zhang G, Sun M, Chu C, Li F, **Wang L**, Cui R, Liu R. CD24 is a genetic modifier for risk and progression of prostate cancer. *Mol Carcinog*. 2016 Jul 5. doi: 10.1002/mc.22522. [Epub ahead of print] PMID: 27377469.

\* Corresponding author

## PARTICIPANTS & OTHER COLLABORATING ORGANIZATIONS

University of Alabama at Birmingham:

PI Dr. Lizhong Wang, Co-I Dr. Runhua Liu, Consultant Dr. Shi Wei and Tech

Mercer University School of Medicine

Co-I Dr. Wei-Hsiung Yang

## SPECIAL REPORTING REQUIREMENTS

None

## APPENDICES

None

## References

1. Knudsen, B.S., and Vasioukhin, V. (2010). Mechanisms of prostate cancer initiation and progression. *Adv Cancer Res* 109, 1-50.
2. Shen, M.M., and Abate-Shen, C. (2010). Molecular genetics of prostate cancer: new prospects for old challenges. *Genes Dev* 24, 1967-2000.
3. DeMarzo, A.M., Nelson, W.G., Isaacs, W.B., and Epstein, J.I. (2003). Pathological and molecular aspects of prostate cancer. *Lancet* 361, 955-964.
4. Ellwood-Yen, K., Graeber, T.G., Wongvipat, J., Iruela-Arispe, M.L., Zhang, J., Matusik, R., Thomas, G.V., and Sawyers, C.L. (2003). Myc-driven murine prostate cancer shares molecular features with human prostate tumors. *Cancer Cell* 4, 223-238.
5. Wang, S., Gao, J., Lei, Q., Rozengurt, N., Pritchard, C., Jiao, J., Thomas, G.V., Li, G., Roy-Burman, P., Nelson, P.S., et al. (2003). Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. *Cancer Cell* 4, 209-221.
6. Hori, S., Nomura, T., and Sakaguchi, S. (2003). Control of regulatory T cell development by the transcription factor Foxp3. *Science* 299, 1057-1061.
7. Chen, G.Y., Chen, C., Wang, L., Chang, X., Zheng, P., and Liu, Y. (2008). Cutting edge: Broad expression of the FoxP3 locus in epithelial cells: a caution against early interpretation of fatal inflammatory diseases following in vivo depletion of FoxP3-expressing cells. *J Immunol* 180, 5163-5166.
8. Wang, L., Liu, R., Li, W., Chen, C., Katoh, H., Chen, G.Y., McNally, B., Lin, L., Zhou, P., Zuo, T., et al. (2009). Somatic single hits inactivate the X-linked tumor suppressor FOXP3 in the prostate. *Cancer Cell* 16, 336-346.
9. Katoh, H., Qin, Z.S., Liu, R., Wang, L., Li, W., Li, X., Wu, L., Du, Z., Lyons, R., Liu, C.G., et al. (2011). FOXP3 orchestrates H4K16 acetylation and H3K4 trimethylation for activation of multiple genes by recruiting MOF and causing displacement of PLU-1. *Mol Cell* 44, 770-784.
10. Suzuki, H., Freije, D., Nusskern, D.R., Okami, K., Cairns, P., Sidransky, D., Isaacs, W.B., and Bova, G.S. (1998). Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues. *Cancer Res* 58, 204-209.
11. Yoshimoto, M., Cunha, I.W., Coudry, R.A., Fonseca, F.P., Torres, C.H., Soares, F.A., and Squire, J.A. (2007). FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome. *Br J Cancer* 97, 678-685.
12. Barbieri, C.E., Baca, S.C., Lawrence, M.S., Demichelis, F., Blattner, M., Theurillat, J.P., White, T.A., Stojanov, P., Van Allen, E., Stransky, N., et al. (2012). Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. *Nat Genet* 44, 685-689.
13. Grasso, C.S., Wu, Y.M., Robinson, D.R., Cao, X., Dhanasekaran, S.M., Khan, A.P., Quist, M.J., Jing, X., Lonigro, R.J., Brenner, J.C., et al. (2012). The mutational landscape of lethal castration-resistant prostate cancer. *Nature* 487, 239-243.
14. Shaw, R.J., and Cantley, L.C. (2006). Ras, PI(3)K and mTOR signalling controls tumour cell growth. *Nature* 441, 424-430.
15. Ratnacaram, C.K., Teletin, M., Jiang, M., Meng, X., Chambon, P., and Metzger, D. (2008). Temporally controlled ablation of PTEN in adult mouse prostate epithelium generates a model of invasive prostatic adenocarcinoma. *Proc Natl Acad Sci U S A* 105, 2521-2526.

16. Trotman, L.C., Niki, M., Dotan, Z.A., Koutcher, J.A., Di Cristofano, A., Xiao, A., Khoo, A.S., Roy-Burman, P., Greenberg, N.M., Van Dyke, T., et al. (2003). Pten dose dictates cancer progression in the prostate. *PLoS Biol* 1, E59.
17. Majumder, P.K., Yeh, J.J., George, D.J., Febbo, P.G., Kum, J., Xue, Q., Bikoff, R., Ma, H., Kantoff, P.W., Golub, T.R., et al. (2003). Prostate intraepithelial neoplasia induced by prostate restricted Akt activation: the MPAKT model. *Proc Natl Acad Sci U S A* 100, 7841-7846.
18. Kremer, C.L., Klein, R.R., Mendelson, J., Browne, W., Samadzedeh, L.K., Vanpatten, K., Highstrom, L., Pestano, G.A., and Nagle, R.B. (2006). Expression of mTOR signaling pathway markers in prostate cancer progression. *Prostate* 66, 1203-1212.
19. Chen, M.L., Xu, P.Z., Peng, X.D., Chen, W.S., Guzman, G., Yang, X., Di Cristofano, A., Pandolfi, P.P., and Hay, N. (2006). The deficiency of Akt1 is sufficient to suppress tumor development in Pten<sup>+/-</sup> mice. *Genes Dev* 20, 1569-1574.
20. Furic, L., Rong, L., Larsson, O., Koumakpayi, I.H., Yoshida, K., Brueschke, A., Petroulakis, E., Robichaud, N., Pollak, M., Gaboury, L.A., et al. (2010). eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression. *Proc Natl Acad Sci U S A* 107, 14134-14139.
21. Hsieh, A.C., Liu, Y., Edlind, M.P., Ingolia, N.T., Janes, M.R., Sher, A., Shi, E.Y., Stumpf, C.R., Christensen, C., Bonham, M.J., et al. (2012). The translational landscape of mTOR signalling steers cancer initiation and metastasis. *Nature* 485, 55-61.
22. Laplante, M., and Sabatini, D.M. (2012). mTOR signaling in growth control and disease. *Cell* 149, 274-293.
23. Wullschleger, S., Loewith, R., and Hall, M.N. (2006). TOR signaling in growth and metabolism. *Cell* 124, 471-484.
24. Kladney, R.D., Cardiff, R.D., Kwiatkowski, D.J., Chiang, G.G., Weber, J.D., Arbeit, J.M., and Lu, Z.H. (2010). Tuberous sclerosis complex 1: an epithelial tumor suppressor essential to prevent spontaneous prostate cancer in aged mice. *Cancer Res* 70, 8937-8947.
25. Rosner, M., Hofer, K., Kubista, M., and Hengstschlager, M. (2003). Cell size regulation by the human TSC tumor suppressor proteins depends on PI3K and FKBP38. *Oncogene* 22, 4786-4798.
26. Ravitz, M.J., Chen, L., Lynch, M., and Schmidt, E.V. (2007). c-myc Repression of TSC2 contributes to control of translation initiation and Myc-induced transformation. *Cancer Res* 67, 11209-11217.
27. Schmidt, E.V., Ravitz, M.J., Chen, L., and Lynch, M. (2009). Growth controls connect: interactions between c-myc and the tuberous sclerosis complex-mTOR pathway. *Cell Cycle* 8, 1344-1351.
28. Wang, J., Kobayashi, T., Floc'h, N., Kinkade, C.W., Aytes, A., Dankort, D., Lefebvre, C., Mitrofanova, A., Cardiff, R.D., McMahon, M., et al. (2012). Braf activation cooperates with Pten loss to regulate c-Myc activation in advanced prostate cancer. *Cancer Res*, in press.
29. Lutterbach, B., and Hann, S.R. (1994). Hierarchical phosphorylation at N-terminal transformation-sensitive sites in c-Myc protein is regulated by mitogens and in mitosis. *Mol Cell Biol* 14, 5510-5522.
30. Sears, R., Leone, G., DeGregori, J., and Nevins, J.R. (1999). Ras enhances Myc protein stability. *Mol Cell* 3, 169-179.

31. Sears, R., Nuckolls, F., Haura, E., Taya, Y., Tamai, K., and Nevins, J.R. (2000). Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. *Genes Dev* *14*, 2501-2514.
32. Hsu, P.P., Kang, S.A., Rameseder, J., Zhang, Y., Ottina, K.A., Lim, D., Peterson, T.R., Choi, Y., Gray, N.S., Yaffe, M.B., et al. (2011). The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. *Science* *332*, 1317-1322.
33. Yu, Y., Yoon, S.O., Poulogiannis, G., Yang, Q., Ma, X.M., Villen, J., Kubica, N., Hoffman, G.R., Cantley, L.C., Gygi, S.P., et al. (2011). Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling. *Science* *332*, 1322-1326.
34. Balakumaran, B.S., Porrello, A., Hsu, D.S., Glover, W., Foye, A., Leung, J.Y., Sullivan, B.A., Hahn, W.C., Loda, M., and Febbo, P.G. (2009). MYC activity mitigates response to rapamycin in prostate cancer through eukaryotic initiation factor 4E-binding protein 1-mediated inhibition of autophagy. *Cancer Res* *69*, 7803-7810.
35. Lin, C.J., Cencic, R., Mills, J.R., Robert, F., and Pelletier, J. (2008). c-Myc and eIF4F are components of a feedforward loop that links transcription and translation. *Cancer Res* *68*, 5326-5334.
36. Rosenwald, I.B., Rhoads, D.B., Callanan, L.D., Isselbacher, K.J., and Schmidt, E.V. (1993). Increased expression of eukaryotic translation initiation factors eIF-4E and eIF-4A in response to growth induction by c-myc. *Proc Natl Acad Sci U S A* *90*, 6175-6178.
37. Schmidt, E.V. (1999). The role of c-myc in cellular growth control. *Oncogene* *18*, 2988-2996.
38. Clegg, N.J., Couto, S.S., Wongvipat, J., Hieronymus, H., Carver, B.S., Taylor, B.S., Ellwood-Yen, K., Gerald, W.L., Sander, C., and Sawyers, C.L. (2011). MYC cooperates with AKT in prostate tumorigenesis and alters sensitivity to mTOR inhibitors. *PLoS One* *6*, e17449.
39. Majumder, P.K., Febbo, P.G., Bikoff, R., Berger, R., Xue, Q., McMahon, L.M., Manola, J., Brugarolas, J., McDonnell, T.J., Golub, T.R., et al. (2004). mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. *Nat Med* *10*, 594-601.
40. Thoreen, C.C., Kang, S.A., Chang, J.W., Liu, Q., Zhang, J., Gao, Y., Reichling, L.J., Sim, T., Sabatini, D.M., and Gray, N.S. (2009). An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. *Journal of Biological Chemistry* *284*, 8023-8032.
41. Ilic, N., Utermark, T., Widlund, H.R., and Roberts, T.M. (2011). PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axis. *Proc Natl Acad Sci U S A* *108*, E699-708.
42. Liu, Q., Chang, J.W., Wang, J., Kang, S.A., Thoreen, C.C., Markhard, A., Hur, W., Zhang, J., Sim, T., Sabatini, D.M., et al. (2010). Discovery of 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benz o[h][1,6]naphthyridin-2(1H)-one as a highly potent, selective mammalian target of rapamycin (mTOR) inhibitor for the treatment of cancer. *J Med Chem* *53*, 7146-7155.

43. Peterson, T.R., Sengupta, S.S., Harris, T.E., Carmack, A.E., Kang, S.A., Balderas, E., Guertin, D.A., Madden, K.L., Carpenter, A.E., Finck, B.N., et al. (2011). mTOR complex 1 regulates lipin 1 localization to control the SREBP pathway. *Cell* *146*, 408-420.
44. Yeh, E., Cunningham, M., Arnold, H., Chasse, D., Monteith, T., Ivaldi, G., Hahn, W.C., Stukenberg, P.T., Shenolikar, S., Uchida, T., et al. (2004). A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells. *Nat Cell Biol* *6*, 308-318.
45. Liu, L., and Eisenman, R.N. (2012). Regulation of c-Myc Protein Abundance by a Protein Phosphatase 2A-Glycogen Synthase Kinase 3beta-Negative Feedback Pathway. *Genes Cancer* *3*, 23-36.
46. Farrell, A.S., Pelz, C., Wang, X., Daniel, C.J., Wang, Z., Su, Y., Janghorban, M., Zhang, X., Morgan, C., Impey, S., et al. (2013). Pin1 Regulates the Dynamics of c-Myc DNA Binding To Facilitate Target Gene Regulation and Oncogenesis. *Mol Cell Biol* *33*, 2930-2949.
47. Vervoorts, J., Luscher-Firzlaff, J., and Luscher, B. (2006). The ins and outs of MYC regulation by posttranslational mechanisms. *J. Biol. Chem.* *281*, 34725-34729.
48. Muellner, M.K., Uras, I.Z., Gapp, B.V., Kerzendorfer, C., Smida, M., Lechtermann, H., Craig-Mueller, N., Colinge, J., Duernberger, G., and Nijman, S.M. (2011). A chemical-genetic screen reveals a mechanism of resistance to PI3K inhibitors in cancer. *Nat Chem Biol* *7*, 787-793.
49. Kang, S.A., Pacold, M.E., Cervantes, C.L., Lim, D., Lou, H.J., Ottina, K., Gray, N.S., Turk, B.E., Yaffe, M.B., and Sabatini, D.M. (2013). mTORC1 phosphorylation sites encode their sensitivity to starvation and rapamycin. *Science* *341*, 1236566.
50. Thoreen, C.C., Chantranupong, L., Keys, H.R., Wang, T., Gray, N.S., and Sabatini, D.M. (2012). A unifying model for mTORC1-mediated regulation of mRNA translation. *Nature* *485*, 109-113.
51. Thoreen, C.C., Kang, S.A., Chang, J.W., Liu, Q., Zhang, J., Gao, Y., Reichling, L.J., Sim, T., Sabatini, D.M., and Gray, N.S. (2009). An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. *J Biol Chem* *284*, 8023-8032.
52. Huang, M.J., Cheng, Y.C., Liu, C.R., Lin, S., and Liu, H.E. (2006). A small-molecule c-Myc inhibitor, 10058-F4, induces cell-cycle arrest, apoptosis, and myeloid differentiation of human acute myeloid leukemia. *Exp Hematol* *34*, 1480-1489.
53. Gomez-Curet, I., Perkins, R.S., Bennett, R., Feidler, K.L., Dunn, S.P., and Krueger, L.J. (2006). c-Myc inhibition negatively impacts lymphoma growth. *J Pediatr Surg* *41*, 207-211; discussion 207-211.
54. Mo, H., and Henriksson, M. (2006). Identification of small molecules that induce apoptosis in a Myc-dependent manner and inhibit Myc-driven transformation. *Proc Natl Acad Sci U S A* *103*, 6344-6349.
55. Wang, H., Hammoudeh, D.I., Follis, A.V., Reese, B.E., Lazo, J.S., Metallo, S.J., and Prochownik, E.V. (2007). Improved low molecular weight Myc-Max inhibitors. *Mol Cancer Ther* *6*, 2399-2408.
56. Shappell, S.B., Thomas, G.V., Roberts, R.L., Herbert, R., Ittmann, M.M., Rubin, M.A., Humphrey, P.A., Sundberg, J.P., Rozengurt, N., Barrios, R., et al. (2004). Prostate pathology of genetically engineered mice: definitions and classification. The consensus

report from the Bar Harbor meeting of the Mouse Models of Human Cancer Consortium  
Prostate Pathology Committee. *Cancer Res* 64, 2270-2305.